Biogen’s Alzheimer’s Breakthroughs: Could AHEAD 3-45 Redefine Early Treatment?

Biogen’s second-quarter 2025 results present a mixed picture regarding its financial and operational performance. The company reported overall revenue growth driven largely by the increasing demand for its newer products, despite continued challenges in its core multiple sclerosis (MS) business. The new product launches, such as VUMERITY, LEQEMBI, ZURZUVAE, and SKYCLARYS, showed significant sequential sales growth. LEQEMBI, in particular, contributed notably to Biogen’s revenue with $160 million in global end-market sales, despite pharmaceutical sales dynamics in China temporarily boosting figures. The company’s concerted efforts to grow its market presence for these products appear to be paying dividends, offsetting declines in older products.